Kingswood Wealth Advisors LLC Decreases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Kingswood Wealth Advisors LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 34.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 14,591 shares of the biopharmaceutical company's stock after selling 7,735 shares during the period. Kingswood Wealth Advisors LLC's holdings in Gilead Sciences were worth $1,348,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of GILD. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences in the 3rd quarter worth approximately $25,000. Valued Wealth Advisors LLC raised its stake in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 161 shares in the last quarter. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences during the fourth quarter worth $29,000. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences during the 2nd quarter valued at $33,000. Finally, Quarry LP purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at $43,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Performance

NASDAQ GILD traded down $1.50 on Tuesday, reaching $93.85. 7,405,270 shares of the company's stock traded hands, compared to its average volume of 6,868,622. The stock has a 50 day moving average price of $91.88 and a 200-day moving average price of $85.27. The firm has a market cap of $116.96 billion, a price-to-earnings ratio of 1,042.78, a P/E/G ratio of 1.31 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company's revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.29 earnings per share. Equities research analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.28%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences's dividend payout ratio (DPR) is 3,422.22%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent research reports. Wells Fargo & Company raised their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Cantor Fitzgerald restated a "neutral" rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Morgan Stanley raised shares of Gilead Sciences from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $87.00 to $113.00 in a research report on Friday, January 10th. Truist Financial increased their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a research report on Friday, November 8th. Finally, UBS Group lifted their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a report on Thursday, November 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $97.96.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock worth $42,130,461 in the last three months. Company insiders own 0.16% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.